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The alarming increase in antibiotic resistance calls for new approaches to study and diagnose 
bacterial infections. In my thesis, I worked at the intersection of microbiology, 
microfabrication, and optical probes to develop novel diagnostic and screening assays for 
microbiology and elucidate bacterial pathogenesis in urinary tract infections (UTI).  
Conventional antibiotic susceptibility testing (AST) has an 18 h turnaround time and low 
throughput. Papers I & II describe the development and validation of the nanowell AST 
(nwAST). This method was based on the nanowell slide (nwSlide), which is a miniaturized 
nanotiter well plate featuring 672 nanowells of 500 nl each. Owing to this large number of 
wells, we designed a quantitative AST that determines a minimum inhibitory concentration 
for up to 6 antibiotics. Validation with 70 UPEC clinical isolates showed a 97.9 % overall 
categorical agreement with agar disc diffusion and a turnaround time between 
3 h 40 min - 8 h 10 min. Key to this short turnaround time was the implementation of the Tlag 
algorithm, which identified the exact time point when bacteria started to grow. This analysis 
delivered results up to 5 times faster compared to conventional AST. Overall, our high 
throughput nwAST surpassed FDA’s requirement of > 90 % categorical agreement. 
The agar plate and 96-well plate offer a limited resolution for bacterial phenotypic screening. 
To improve screening resolution, in paper III we took advantage of the nwSlide’s versatility 
and combined it with fluorescence-activated cell sorting. We developed a rapid workflow to 
directly select and single-sort bacterial mutants in individual nanowells, based on a 
fluorescence-encoding transposon. Sorted mutants were phenotypically screened for growth, 
morphology, and metabolism already during the first incubation on the nanowell slide using 
spectrophotometry, algorithmic analysis and microscopy. Selected phenotypes were retrieved 
and screened with single-primer PCR and sequencing to identify the transposon insertion site. 
By leveraging the versatility of the nwSlide, we developed a high-resolution screening 
platform, with higher throughput and less reagent consumption compared to the agar plate 
and 96-well plate. 
In paper IV, we developed a proximal tubule-on-a-chip (PToC) based on a microfluidic 
device. We delineated UPEC's adhesion to renal epithelial cells under shear stress with 
temporal and single-cell resolution. We demonstrated that only a minority of cells adhered 
and withstood shear stress for > 30 min. This binding was PapG-independent. Adherent 
bacteria divided rapidly and eventually formed microcolonies, which were mediated by FimH 
adhesin. Microcolonies expanded colonization beyond the cell surface, enhanced infection 
spread, and extended bacterial binding under shear stress from minutes to hours. Although the 
absence of PapG and FimH delayed infection, UPEC eventually colonized renal cells causing 
them to round up and slough off. These results showed that UPEC has a repertoire of 
redundant adhesion organelles that help bacteria to withstand shear stress in the urinary tract. 
Detection of biofilm is absent in clinical diagnostics, despite its association with antibiotic 
tolerance. In paper V, we developed a rapid diagnostic assay for biofilm-associated UTI 
called optotracing. This assay is based on heptamer formyl thiophene acetic acid, a 
luminescent conjugated oligothiophene. This molecule produces a unique spectral signature 
upon binding to cellulose, which is an extracellular component in biofilms of UPEC. We first 
optimized optotracing’s performance in PBS and healthy urine spiked with UPEC biofilm or 
purified cellulose. Next, we developed a workflow to isolate and screen urine sediment for 
cellulose within 45 min. Optotracing of 182 urine samples from UTI patients and 
interpretation of results with principal component analysis and k-means clustering identified 
27 urine samples as positive for cellulose. This result provided the first direct evidence of 
biofilm formation in UTI. With a short turnaround time and minimum equipment 




POPULAR SCIENCE SUMMARY 
The widespread emergence of antibiotic resistance has brought bacterial infections back to 
the spotlight. Today, more than ever, there is a need to increase our understanding of bacterial 
pathogenesis and apply this knowledge on new approaches for prevention, diagnosis, and 
treatment. In my thesis, I combined microbiology with new technologies to improve the study 
and diagnosis of urinary tract infections. 
Clinicians often have no choice but to prescribe antibiotics based on a clinical educated 
guess, as diagnostics to identify the right treatment may take several days to deliver results. 
However, this approach can be ineffective and it can also promote harmless bacteria in our 
body to become resistant. In papers I & II, we developed a diagnostic test to help clinicians 
choose the right antibiotic. This test was based on the nanowell slide, a miniature device that 
fits in the palm of a hand. In the 672 tiny wells of the nanowell slide, bacteria were incubated 
with different antibiotics. Based on the amount of light that passed through the transparent 
bottom of these wells, we could understand how bacteria responded to antibiotics. A 
decreasing amount of light indicated growth of resistant bacteria, whereas a constant high 
amount of light indicated inhibition of susceptible bacteria. Key to rapid diagnosis was an 
algorithm that processed the changes of light and detected resistant bacteria within 3-8 h. The 
accurate and timely diagnosis of this test could help clinicians prescribe the right antibiotic 
fast, thus improving patient outcome and reducing antibiotic resistance.  
The ability of bacteria to thrive in so many different environments lies in their genes. 
However, it is not always easy to pinpoint the genes behind different characteristics of 
bacteria. In paper III, we approached this problem by randomly “turning off” bacterial 
genes. Hundreds of bacteria with different genes deactivated were encapsulated one by one in 
small droplets and added in the nanowell slide. While they multiplied in the wells, we 
examined them in detail with light measurements, microscopy, and algorithmic analysis. 
Bacteria with abnormal growth, metabolism, and morphology were picked to identify which 
of their genes had been deactivated. By doing so, we associated specific genes with different 
bacterial characteristics. Using our approach, microbiologists could understand the role of 
bacterial genes in a more detailed and user-friendlier way compared to other methods.  
Uropathogenic bacteria can move up in the urinary tract and infect the kidneys without being 
flushed away by urine. In paper IV, we simulated the kidney environment in a device with 
small transparent channels to understand how bacteria resist urine flow. Each channel 
contained a single layer of kidney cells, which was exposed to uropathogenic Escherichia 
coli under flow conditions. Using time-lapse microscopy, we saw that only a few bacteria 
were fit enough to attach to cells. These so-called “settlers” of the infection multiplied 
rapidly, forming small colonies on the cells. Colonies protected bacteria against the flow and 
produced new bacteria to spread the infection. Key to the resistance of settlers and colonies 
against the flow was some sticky rods on bacteria’s surface. Using these rods called fimbriae, 
bacteria attached to renal cells, but also to each other to form microcolonies. Understanding 
how bacteria cause infection can lead to better prevention and treatment. Moreover, 
replication of organ functions in devices has the potential to reduce and replace the use of 
experimental animals.  
Bacteria living in colonies covered with a slimy film of proteins and polysaccharides are 
known as biofilms. In a biofilm, bacteria are more tolerant to antibiotics than they are alone. 
Therefore, if a biofilm forms in a patient, it can lead to a chronic infection. Despite posing a 
threat to our health, there are currently no diagnostic methods for biofilm. In paper V, we 
used a fluorescent molecule to develop the first diagnostic test for biofilm in urinary tract 
infections. This molecule detects cellulose, a biofilm component of uropathogenic 
Escherichia coli. Based on this property, we screened 182 urine samples from UTI patients 
and identified 27 as cellulose-positive. Because humans do not produce cellulose, its 
detection in urine showed that bacteria had formed biofilm in the urinary tract of these 
patients. The possibility to detect biofilm could help clinicians prescribe better-tailored 
antibiotic therapies to patients. 
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1 INTRODUCTION 
1.1 THE RISE OF ANTIBIOTIC RESISTANCE 
The monumental discovery of penicillin by Sir Alexander Fleming in 1929 (1), followed by a 
golden age of antibiotic discovery between 1950-1960, made antibiotics the bedrock of 
modern medicine and heralded the end of bacterial infections as a health threat (2). Fast 
forward to 2018, and health organizations are devising action plans to face a post-antibiotic 
era (3–5). Antibiotic resistant “superbugs” make headlines every week, and the pipeline for 
new antibiotics is drying out (6). It is estimated that 25,000 people in Europe and 23,000 
people in the United States die every year due to infections from antibiotic resistant bacteria 
(3, 4). What led to the emergence of antibiotic resistance should come as no surprise. During 
his Nobel Lecture on penicillin in 1945, Fleming had already warned: 
The time may come when penicillin can be bought by anyone in the shops. Then there is the 
danger that the ignorant man may easily underdose himself and by exposing his microbes to 
non-lethal quantities of the drug make them resistant. (7) 
Indeed, misuse, but also indiscriminate overuse of antibiotics, has led to a high selective 
pressure among bacteria, and unavoidably to development of resistance (8). However, the 
early euphoria surrounding antibiotics and the high discovery rate of new antibiotics in 
previous decades made us underestimate the ability of bacteria to evolve in the long run. The 
exclusive reliance on antibiotic treatment came at the expense of infection research, 
prevention, and diagnosis. Today, besides antibiotic discovery, bacterial pathogenesis itself 
has to be revisited. Since the dawn of modern microbiology in Koch's era, causality between 
pathogen and disease has proved complex. Multifactorial virulence, heterogeneity, and 
biofilms are some of the concepts that require thorough investigation to unravel the 
complexity of bacterial pathogenesis fully. Findings deriving from the study of bacterial 
pathogenesis should serve as the cornerstone for improving prevention, diagnosis, and 
treatment to deal with antibiotic resistance. In these efforts, technology should play a central 
role to move the field of microbiology forward.  
1.2 CAUSALITY BETWEEN BACTERIA AND DISEASE 
Despite bacteria's 3-billion-year presence on our planet, it was not until the 17th century when 
Antonie van Leeuwenhoek directly observed them with his microscopes (9). It took 2 more 
centuries before causality between bacteria and disease was established by Robert Koch (10). 
His pioneering work in microscopy techniques, in vitro bacterial cultures, and animal models 
enabled Koch to demonstrate bacteria as causative agents for anthrax, cholera, and 
tuberculosis (10). While researching the etiology of tuberculosis, he proposed 4 postulates as 
a framework to establish causality between bacteria and disease (11):  
(i) Bacteria should be present only in diseased and not in healthy individuals  
(ii) Bacteria should be isolated in pure culture 
(iii) Isolated bacteria should cause the disease in a healthy experimental host  
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(iv) Bacteria should be isolated anew from the diseased experimental host 
Although these postulates led to the identification of several new pathogens, they were not 
universal (12). As new molecular methods became available, microbiologists obtained a more 
refined view of bacterial pathogenesis. Not only was disease linked to specific bacteria, but 
also to specific genes, termed virulence factors. Based on this new knowledge, the Koch’s 
postulates were modified into the Molecular Koch’s postulates (12, 13): 
(i) The gene suspected to cause disease should be present only in virulent and not in 
avirulent bacteria 
(ii) Inactivation of the gene should mitigate pathogenicity or introduction of the gene 
in an avirulent strain should confer pathogenicity 
(iii) The gene should be expressed in the host during infection  
The original and molecular postulates have a conceptual and technical aspect (14).  The 
conceptual aspect concerns the natural disease development and microbial pathogenesis, 
whereas the technical aspect encompasses the methods available to detect, isolate and culture 
bacteria or to manipulate their genome. Looking at causality through the conceptual aspect, 
we can identify several examples from infection biology that fail to conform to the postulates. 
Pathogenicity is not only an intrinsic bacterial property, but it also depends on the microbe-
host interaction. For instance, bacteria avirulent by definition can turn into opportunistic 
pathogens when the host’s immune system becomes compromised (15), or benign 
commensal bacteria of the intestinal flora can cause disease upon entry to a different body 
site (Fig. 1) (12). Multifactorial virulence is another example where conceptual and technical 
aspects of the postulates are not satisfied. The ability of bacteria to cause disease can be 
traced not only back to one, but also back to a synergy of virulence factors (Fig. 1). 
Inactivation of single virulence factors in acute infections, such as the toxin of Vibrio 
cholerae or the capsule of Streptococcus pneumoniae, led to an apparent loss of pathogenicity 
(13, 16). In other infections, however, virulence factors deviate from their traditional 
definition. Their role is contributory instead of requisite, and they act in synergy with other 
factors (16). As they confer a competitive advantage without being a prerequisite for 
infection establishment, they are better described as fitness factors (17, 18). These factors can 
be transiently and heterogeneously expressed in a bacterial population, depending on the 
infection stage and the cues from the host’s microenvironment (12)(19). Biofilm-associated 
infections are yet another group of infections that departs from the conceptual aspects of the 
postulates (Fig. 1). Biofilms can be mono- or polymicrobial, with a different microbial 
composition among patients suffering from the same type of infection (20). Their formation 
is orchestrated by complex gene networks in response to several external cues, making it 
difficult to link the disease to specific bacterial factors. 
Addressing these new concepts of bacterial pathogenesis can be technically hard. To 
investigate the role of the immune system and host tissue in bacterial pathogenesis, clinically 
and physiologically relevant infection models are needed. Assessing the role of fitness factors 
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Fig. 1 Examples of bacterial pathogenesis outside the conceptual scope of the original and molecular Koch’s 
postulates. Bacterial pathogenicity can depend on the status of the host immune system (top left panel) and the anatomical 
site of the host (top right panel). It can be mediated by a single virulence factor, which is a prerequisite for the infection, or by 
several factors with a contributory role to overall virulence (bottom left panel). Expression of these factors can be 
heterogeneous in the bacterial population (bottom left panel). Bacterial pathogenicity can also depend on the bacterial 
lifestyle, with planktonic bacteria associated with acute infections and biofilm with chronic infections (bottom right panel). 
requires models with spatiotemporal resolution. This resolution is currently lacking in 
sacrificial animal models, where infection is examined at the infection endpoint by measuring 
the bacterial load in harvested organs or by performing an immunohistological examination 
(13). Phenotypic bacterial heterogeneity requires yet another parameter to be added in 
infection models: the single-cell resolution. Finally, detection of biofilm-associated infections 
is currently absent. New biofilm-specific methods need to be developed, as current 
diagnostics are designed to detect, isolate and grow planktonic bacteria.  
Through these examples, it becomes evident that Koch’s original and molecular postulates 
are not to be used as dogma, but rather as a guide to scientific thinking. However, even when 
an infection does not fulfill a postulate, it should be seen as an opportunity to understand 
bacterial pathogenesis better. In the following sections, we describe how technical 
innovations can help us understand the role of tissue physiology, multifactorial virulence, and 
biofilm in urinary tract infections, which are cases of bacterial pathogenesis that fall outside 
the conceptual scope of the postulates.  
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1.2.1 Spatiotemporal studies of bacterial pathogenesis in pyelonephritis: 
The paradigm of P and Type 1 fimbriae synergy 
Pyelonephritis represents an upper urinary tract infection (UTI) targeting the kidneys. More 
than 70 % of acute cases of pyelonephritis are caused by Uropathogenic Escherichia coli 
(UPEC) (21), an otherwise benign commensal in the gut flora (22). Typically, bacteria enter 
the urinary tract through the urethra and eventually reach the bladder, where they cause 
cystitis (23). Further ascension to the kidneys via the ureters leads to pyelonephritis, which is 
characterized as a tubulointerstitial disorder (24). Although less common than cystitis, 
pyelonephritis entails the risk of leading to urosepsis (25).  
The kidney, a normally sterile organ, is anatomically and physiologically challenging for 
bacteria to infect (26). The morphology of the renal epithelium is far from uniform along its 
different segments (27) and constantly descending flow of urine generates shear stress along 
this single-layer epithelium. Infection establishment under these conditions depends on 
UPEC's ability to bind specific host cell receptors on the renal epithelium and to withstand 
shear stress. Binding is conferred by a group of adhesion organelles, called fimbriae (28). A 
fimbrial operon encountered in ≈ 80 % of pyelonephritic isolates is the pap operon, which 
encodes P fimbriae (29). This high prevalence of pap operon suggested that P fimbriae 
provide UPEC with an advantage to infect the kidneys. Indeed, P fimbriae bind via their 
PapG tip adhesin to Gal(α1-4)Gal moieties found on the glycolipid globoseries of the renal 
epithelium (30–33). PapG has three variants, classes I, II and III, with class II mainly 
associated with pyelonephritis in humans (34, 35). Although several studies have been 
performed using sacrificial animal models of the ascending UTI, findings on the role of P 
fimbriae in pyelonephritis are inconsistent (36). Differences in animal models, UPEC strains 
and mutagenesis methods used may account for these inconsistencies (36). For instance, a 
study conducted with a P fimbrial mutant of UPEC strain HU734 showed reduced bacterial 
loads in kidneys of CBA mice (37), whereas another study in the same mouse model using an 
isogenic papG mutant of UPEC CFT073 showed only a subtle role for P fimbriae (38). 
Mutants were constructed with chemical mutagenesis in the first study and allelic exchange 
mutagenesis in the second. Therefore, secondary mutations caused by the less precise 
chemical mutagenesis may have accounted for the decreased virulence observed. In a third 
study using the isogenic papG mutant of UPEC DS17 in a monkey model, renal pathology 
was attenuated compared to WT infection (39). PapG receptors are present in both mice and 
monkeys, but differences in the patterns of isoreceptors may affect host specificity (40). 
Additionally, we have to take into account that the immune response to P fimbriae differs 
among animal models (36).  Regardless of the results, all these studies performed in 
sacrificial animal models had one thing in common. They were investigating the role of P 
fimbriae solely in the context of the infection outcome. Real-time monitoring of 
pyelonephritis, using the 2-photon microscopy-based intravital rat model, provided new 
insight into the role of P fimbriae (41). In this model UPEC CFT073 rapidly colonized the 
renal proximal tubule, leading to major alterations in tissue homeostasis. When compared to 
an isogenic papG mutant, it was shown that P fimbriae enhanced initial adhesion to the 
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epithelium of proximal tubules, but they were not a requirement for the establishment of 
pyelonephritis, suggesting that P fimbriae act as a fitness rather than a virulence factor (42).  
By studying pyelonephritis in the intravital rat model under a spatiotemporal resolution, a 
new role was also shown for Type 1 fimbriae. These fimbriae, which are encoded by operon 
fim, are present in virtually all UPEC strains (43, 44). They are traditionally associated with 
cystitis, where they mediate adhesion to the bladder epithelium (45, 46). Their tip adhesin, 
FimH, binds to the terminally exposed mannose residues of Uroplakin Ia. This is a major 
protein of the urothelial plaques found on the superficial umbrella cells comprising the 
bladder epithelium (45–47). Besides this role, the intravital model showed that FimH enabled 
bacteria to expand colonization towards the lumen of the proximal tubule, leading to nephron 
obstruction (42). This finding suggested that FimH mediates interbacterial interactions by 
binding to mannose residues of LPS (48). Similar to PapG, FimH was not a prerequisite for 
infection establishment (42). Therefore, both adhesins act rather as fitness factors. Through 
their synergistic action, UPEC better withstands the flow of primary filtrate in the proximal 
tubules, resulting in a faster and more efficient progression of the infection. This highlights 
the need to use spatiotemporal rather than sacrificial animal models to obtain the full picture 
of bacterial pathogenesis. 
1.2.2 Bacterial biofilms in infection: An emerging threat 
Biofilm has emerged during the last 3 decades from an overlooked parameter of bacterial 
infections to an important contributor of pathogenicity. The term biofilm describes a sessile 
bacterial lifestyle in which bacteria form multicellular aggregated communities embedded in 
a self-secreted extracellular matrix (ECM), composed of proteins, polysaccharides, lipids and 
extracellular DNA (49). The ECM defines a biofilm spatially, affecting parameters such as 
interbacterial interactions, communication with the external environment and nutrient 
distribution (50). As a result, bacteria in biofilms exhibit different properties compared to 
bacteria in a planktonic lifestyle. Whereas planktonic bacteria usually cause acute infections, 
biofilms are often associated with chronic infections, characterized by tolerance to the host's 
immune response and clinically relevant doses of antibiotics (51). Tolerance to antibiotics 
derives from the distinct physiology of bacteria in biofilms, the complex biofilm structure 
itself, but also from the specific microenvironmental conditions at the infection site (52–59). 
Despite the far more severe consequences of biofilm-associated infections, it remains a 
challenge to differentiate between biofilm and planktonic bacteria in a patient. 
1.2.2.1 Diagnostic challenges in biofilm-associated infections 
Diagnostic methods routinely used for bacterial infections were developed with the 
planktonic lifestyle in mind, and they are inadequate to detect biofilm in a patient. Biofilm in 
infection results from phenotypic changes triggered by the host’s environment. Consequently, 
this phenotype is quickly lost in culture-based methods, in which bacteria are subcultured 
from a patient sample under conditions that promote planktonic growth (60). Molecular 
methods, such as PCR-based detection of bacterial genes, cannot distinguish either between 
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the distinct phenotype of biofilm and planktonic bacteria, as they detect genotypic traits (61–
63). Therefore, biofilm diagnostics should take place directly in a patient sample and detect 
biofilm-specific phenotypic traits. What clearly distinguishes a biofilm from planktonic 
bacteria is the presence of bacterial aggregates encased in an ECM. Bacterial aggregates can 
be detected directly in a patient sample with light microscopy using non-specific staining 
(e.g., Gram stain) or with confocal microscopy using species-specific fluorescent probes (e.g., 
fluorescence in situ hybridization (FISH) and peptide nucleic acid FISH) (64, 65). Detection 
of ECM components, however, is lagging behind. Carbohydrates in the ECM have been 
visualized using several non-specific stains, such as alcian blue, calcofluor, ruthenium red 
(66, 67) and fluorescently labeled lectins (68, 69), but the interpretation of results is 
somewhat subjective. Immunostaining of biofilm-specific antigens has been applied only in a 
few cases. Such examples are the detection of alginate in Pseudomonas aeruginosa biofilms 
with immunofluorescence (64), and detection of curli in UPEC with electron microscopy 
(70). However, sample preparation in these approaches is laborious and time-consuming. 
Moreover, confocal and electron microscopy are not suitable for routine use in a clinical lab, 
where hundreds of samples arrive daily.  
1.2.2.2 Luminescent conjugated oligothiophenes as a new tool for biofilm detection  
A group of fluorophore reporters, called luminescent conjugated oligothiophenes (LCO), 
holds promise as a new approach for the diagnosis of biofilm-related infections. LCO consist 
of a defined oligothiophene backbone, which forms an extended conjugated π-system (71–
73). Binding of LCO to a target molecule via non-covalent electrostatic and hydrophobic 
interactions causes the oligothiophene backbone to assume a distinct conformation, which 
distorts the extension of the conjugated π-system.  This distortion changes the energy gap 
between the ground and the first excited singlet state, which generates a target-specific optical 
signature (73). Based on this property, LCO act as conformation sensitive optical probes. 
Heptamer formyl thiophene acetic acid (h-FTAA), a molecule of the LCO group, generates a 
distinct optical signature upon binding to cellulose (74, 75). Application of h-FTAA on native 
Salmonella spp biofilms, which contain cellulose as ECM component (76), generated a 
cellulose-specific fluorescent spectrum with an excitation peak at 480 nm (74). This ability to 
rapidly detect cellulose in its native form, together with minimal sample preparation and 
instrumentation requirements (74), could make h-FTAA a suitable candidate for diagnosis of 
biofilm-associated infections. Besides Salmonella spp, Escherichia coli (E. coli), the most 
common pathogen in UTI, also contains cellulose as one of its main biofilm ECM 
components (76). It has been suggested that biofilm may be present in UTI, especially in 
patients suffering from recurrent infections (77–79). Accumulating evidence from animal 
studies have also shown a biofilm-like phenotype in the proximal tubule of the nephrons (42) 
and biofilm-like aggregates in intracellular bacterial communities of the prostate glands (80) 
and the superficial cells of the bladder (81), as well as biofilm-like aggregates in urine from 
UTI patients (82, 83). As all this evidence is based on morphological observations, 
application of h-FTAA could help consolidate a link between UTI and biofilm.
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1.3 THE DIAGNOSTIC WORKFLOW OF URINARY TRACT INFECTIONS 
One of the main contributors to antibiotic resistance is the inappropriate prescription of 
antibiotics (84). This problem mainly stems from untimely diagnosis of antibiotic resistance. 
In the review on antimicrobial resistance, Tackling drug-resistant infections globally: Final 
Report and Recommendations, Jim O'Neill wrote:  
I find it incredible that doctors must still prescribe antibiotics based only on their 
immediate assessment of a patient’s symptoms, just like they used to when antibiotics first 
entered common use in the 1950s. When a test is used to confirm the diagnosis it is often 
based on a slow technology that hasn’t changed significantly since the 1860s. (5) 
Indeed, in a non-life-threatening scenario, an antibiotic prescription may be based only on 
clinical symptoms, without further diagnostics. In a life-threatening scenario, clinicians will 
also proceed to an empirical prescription of broad-spectrum antibiotics to secure a patient's 
life, while waiting for diagnostics to be completed (5). Upon completion of diagnostics, they 
can opt for targeted antibiotic therapy. Both routes to treatment, however, expose patients to 
suboptimal or unnecessary treatment, which contributes to the emergence of resistant bacteria 
(85). Several reports on antibiotic resistance unanimously agree that this issue can only be 
resolved with better and faster diagnostic methods (3, 5, 86).  
The diagnostic workflow in a clinical microbiology laboratory varies depending on the 
patient sample, type of infection and laboratory equipment. To fully characterize the disease-
causing pathogen, several steps are required, which unavoidably results in long turnaround 
times. The following sections present an overview of the 3 main steps in a standard 
diagnostic workflow for UTI: bacteriuria screening, pathogen identification, and antibiotic 
susceptibility testing (AST) (Fig. 2) (87). 
 
Fig. 2 Diagnostic workflow of UTI. Methods used in each diagnostic step are illustrated. The level of antibiotic treatment 
specificity achieved after each diagnostic step is also shown (brown box). 
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1.3.1 Bacteriuria screening 
Laboratory testing for UTI is performed for patients experiencing symptoms, such as dysuria, 
urgency, and frequency (88). The first step in laboratory testing is to confirm or rule out a 
UTI by screening for bacteriuria (Fig. 2). The gold standard to screen for bacteriuria are urine 
cultures on agar plates, which determine the bacterial load in urine (88). Growth of a single or 
predominant uropathogenic species at a concentration of ≥ 1 x 103 cfu/ml indicates UTI in 
symptomatic patients (88). Although quantitative, urine cultures require at least 18-20 h 
incubation before a UTI can be ruled out (89). Therefore, rapid screening methods for 
bacteriuria are needed to avoid unnecessary prescription of antibiotics in patients without a 
UTI, but also to avoid unnecessary workload and costs. A rapid alternative to urine cultures is 
the urine dipstick, which detects a UTI based on the presence of nitrites and leukocyte 
esterases. Despite high specificity, sensitivity can be as low as 43.2 %, depending on the 
patient cohort (90). As only Enterobacteriaceae convert nitrate to nitrite, the dipstick fails to 
detect other uropathogens. Moreover, urine samples can be dilute, especially in small children 
where frequent urination results in nitrite concentration below the limit of detection (90). 
Microscopic analysis of Gram-stained urine samples is an alternative way to screen directly 
for bacteriuria. However, sensitivity and specificity greatly vary (89), and it is a more 
laborious approach compared to the dipstick.  
1.3.2 Pathogen identification 
A UTI is confirmed when a patient presents both clinical symptoms and bacteriuria. 
However, identification of the pathogen species and subsequent antibiotic susceptibility 
testing are still required to avoid a prescription of antibiotics based solely on empirical 
assessment (Fig. 2). Current methods available for pathogen identification are matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), FISH, multiplex 
PCR and automated biochemical assays (87). Although these assays are rapid, they require a 
pure bacterial culture for optimal performance. Therefore, plating of a urine culture on agar 
plates is required to isolate bacteria, which adds 18-20 h to the diagnostic workflow (87). 
Identification of certain species can take place simultaneously if chromoagar is used (91). 
1.3.3 Antibiotic susceptibility testing 
Pathogen identification can guide the clinician to select a species-specific antibiotic based on 
the local antibiogram. A patient-tailored antibiotic therapy, however, can only be designed by 
performing AST (Fig 2). In a typical AST, a standardized inoculum of 5 x 105 cfu/ml from 
the isolated pathogen is tested in growth media containing a 2-fold serial dilution of an 
antibiotic (92). After overnight incubation, each antibiotic dilution is evaluated for bacterial 
growth using visual or instrument-assisted detection. The lowest concentration that 
completely inhibits bacteria from growing is defined as minimum inhibitory concentration 
(MIC) (92). By comparing the MIC to the established clinical breakpoints for that particular 
antibiotic-pathogen combination, the pathogen is classified as resistant, intermediate or 
susceptible. Despite the great value of AST, the turnaround time of current methods exceeds 
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1 day. This long turnaround time is mainly affected by 3 parameters: i) the requirement for a 
pure bacterial inoculum of a standard concentration ii) the method’s sensitivity to detect 
bacterial growth, and iii) the lag phase of bacteria. In the following sections, we assess AST 
technologies used in the clinics based on their performance for the first 2 parameters. 
1.3.3.1 Antibiotic susceptibility testing directly in urine 
AST is optimal when a pure bacterial inoculum of a defined concentration is used. For UTI 
this means that an 18-h urine culture step for pathogen isolation precedes AST (93). Official 
guidelines discourage the direct use of urine as inoculum for AST because it can affect 
bacterial growth kinetics and lead to misinterpretations (94). Urine has a non-standardized 
consistency, which varies significantly between patients in terms of pH, electrolyte 
concentration and other substances, such as antimicrobials (87)(94). It may also contain more 
than one bacterial species, either due to a polymicrobial infection or contamination by 
microflora (94). Several host components in urine, such as erythrocytes, white blood cells, 
and epithelial cells, can also compromise the performance of AST (95). Finally, contrary to 
the standardized inoculum of pure cultures, the bacterial load in urine may be insufficient to 
perform AST directly, as shown with disc diffusion testing (96).  
Accordingly, there are no clinically validated methods for direct AST in urine. One promising 
approach is the addition of urine from a UTI patient in an excess volume of culture media 
containing antibiotics (97, 98). An alternative approach is the sequential filtration of urine 
using 2 filters with different pore sizes to filter out white blood cells and large debris, but to 
retain bacteria (95). However, the authors reported that filter clogging could be an issue. 
Moreover, bacteria had to be counted manually with phase-contrast microscopy to adjust 
their concentration before AST.  Gel electrofiltration, which is integrated into the automated 
system Accelerate PhenoTM, has been used to successfully isolate bacteria from blood 
cultures based on size and charge (99, 100). This approach isolates bacteria from smaller 
contaminating substances in a sample, such as salts, proteins, and cellular debris sample, but 
not from larger particles, such as other contaminating bacteria or host cells (101).  
1.3.3.2 Antibiotic susceptibility testing based on naked eye inspection 
In several of the most widely used AST methods, such as disc diffusion, Etest and broth 
dilution, bacteria's antibiotic susceptibility is determined by naked eye inspection at the 
incubation endpoint (93). A long incubation time of 16-20 h is required for bacteria to reach 
growth levels visible to the unaided eye. In disc diffusion, a paper disc is impregnated with a 
single antibiotic concentration, which diffuses radially around the disc when placed on an 
agar plate inoculated with 1-2 x 108 cfu/ml of bacteria (102). Inhibition of bacterial growth 
leaves a clear zone around the disc. Depending on the diameter of the inhibition zone, the 
pathogen's antibiotic susceptibility is determined. The method's throughput is low to medium; 
up to 6 or 12 discs containing different antibiotics can be used simultaneously depending on 
the agar plate's diameter (90 or 150 mm). Although cost-affordable and simple, disc diffusion 
is only qualitative.  
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Etest is a plastic strip impregnated with an antibiotic concentration gradient. The strip is 
placed on an agar plate with a bacterial inoculum of 1-2 x 108 cfu/ml, and the antibiotic 
gradient diffuses into the agar (92). After overnight incubation, inhibition of bacterial growth 
leaves a clear ellipse-shaped zone. Based on the intersection point of the ellipse zone with the 
strip, the MIC is determined by naked eye observation. Although it delivers a quantitative 
result, Etest has a higher cost compared with disc diffusion and a low to medium throughput 
with 2 or 6 strips fitting per agar plate, depending on the agar plate's diameter (92).  
Broth dilution is the principal liquid media-based AST. In this assay, 5 x 105 cfu/ml of 
bacteria in liquid growth media are tested against a 2-fold serial antibiotic dilution in glass 
tubes. After overnight incubation, visible turbidity in each tube is evaluated to define the MIC 
(103). Although this is a low-cost and quantitative approach, it is not usually performed in the 
diagnostic laboratory, as it is laborious and slow. An improvement of broth dilution was its 
adaptation to a 96-well plate (104). In this format, called microbroth dilution, volume was 
reduced from milli- to microliters (≈100-150 µl/well), and throughput was increased to 
simultaneous testing of 12 antibiotics, with eight 2-fold serial dilutions from each. After 
overnight incubation, the bottom of each well is examined with the help of a mirror for a 
visible bacterial pellet to determine a MIC. 
1.3.3.3 Absorbance-based antibiotic susceptibility testing 
Absorbance-based detection is more sensitive than the unaided eye, with a bacterial growth 
detection limit of 1 x 107 cfu/ml (105). This limit of detection shortens the turnaround time 
significantly because bacteria usually reach a culture concentration of 1 x 107 cfu/ml earlier 
than 16 h. Several automated systems adopted real-time absorbance-based detection of 
bacterial growth in liquid media to achieve faster AST. Systems such as the MicroScan 
WalkAway (106), BD Phoenix Automated Microbiology System (92, 107), and VITEK2 
(108, 109) have turnaround times between 4-16 h, depending on the pathogen tested. Sample 
loading is manual in WalkAway and BD Phoenix and automated in VITEK2 (92). All 3 
instruments offer improved throughput compared with conventional methods, as they run 
multiple tests simultaneously. WalkAway and BD Phoenix have a 96- and 84-microwell 
format respectively (107) and, VITEK2 has a 64-cubicle microfluidic cartridge (110). 
However, only MicroScan WalkAway and BD Phoenix deliver a MIC based on true bacterial 
growth, as they accommodate a complete 2-fold serial dilution range for each antibiotic in 
their panels (105, 111). VITEK2, which features only selected antibiotic concentrations, 
provides a MIC based on algorithmic calculations (112). Overall, AST based on absorbance 
delivers results earlier than AST based on visual inspection but at a much higher cost.  
1.3.3.4 Microscopy-based antibiotic susceptibility testing 
The automated AST instrument, Accelerate Pheno™, based on dark field time-lapse 
microscopy, was recently approved for clinical use (101). Based on microscopy, detection of 
bacterial growth is achieved on a single-cell level. Images of immobilized single bacteria in 
chambers with and without antibiotic are captured over time (101). Computer-assisted 
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analysis of these images calculates bacterial division and deducts a growth rate based on the 
division frequency. By applying a machine-learning algorithm, this growth rate is compared 
to the growth rate of the antibiotic-free control to determine a MIC. This approach achieves a 
turnaround time of ≈ 7 h for Gram-negative bacteria isolated from blood (113). Although 
rapid, the method's throughput is currently low. It can process only one sample per instrument 
module with the possibility to extend up to 8 modules, but at a considerable cost increase 
(113). 
1.3.3.5 Detection of antibiotic resistance with molecular diagnostics 
Molecular methods based on nucleic acid detection, such as PCR, microarrays, and 
sequencing, identify genes or single-nucleotide polymorphisms associated with antibiotic 
resistance (114–117). In a short turnaround time, these methods can show which antibiotics 
could be ineffective based on the genotypic resistance mechanism of the pathogen. Despite a 
positive genotypic result, the pathogen may still be phenotypically susceptible (118). 
Therefore, a phenotypic AST is still required to confirm the genotypic result and to determine 
a MIC. Moreover, molecular methods are limited to pathogens with known resistance 
mechanisms (118). 
1.4 MICROBIOLOGY MEETS MICROFABRICATION 
Fabrication of milli- and micrometer scale devices confer significant advantages to biology 
and medicine (119). Miniaturized devices integrate smoothly with other instruments and 
sensors to develop assays with quantitative multiparametric analysis under accurately 
controlled in vitro conditions (120)(121). Several miniaturized wells or channels can fit 
within small dimensions, dramatically increasing throughput and simultaneously decreasing 
reagent and sample volume requirements. These miniaturized wells and channels better 
match the dimensions of prokaryotic and eukaryotic cells. In combination with an optically 
clear material, they become suitable for single-cell analysis with microscopy and 
spectrophotometric detection methods (122). Besides research, miniaturized devices are also 
ideal for clinical use as point-of-care systems at the clinician's office. All these advantages 
can have a substantial impact on the advancement of microbiology. Here we will discuss how 
bacterial pathogenesis and infection diagnostics could be benefited from the integration of 
microfabricated devices.  
1.4.1 Towards new in vitro infection models  
The intravital animal model for pyelonephritis enabled the study of infection with 
spatiotemporal resolution in its natural milieu, with intact host tissue structure and physiology 
(41). However, animal models come with ethical and technical limitations. These include 
imaging depth in the tissue, exposure time and lack of resolution to image the phenotypic 
heterogeneity of bacteria on a single-cell level. Moreover, gene expression profiling and 
protein detection at the site of infection can be measured only at the infection endpoint, as 
this requires kidney harvesting and subsequent RNA and protein extraction. Most 
importantly, the host-pathogen interplay can be complicated to understand on the organ level, 
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and therefore reduction of the infection down to the level of single tissue or cell line using 
an in vitro model is still required. 
Two-dimensional cell culture models offer great flexibility regarding handling and 
compatibility with analysis methods. Their setup is usually based on a well plate in which 
primary, cancer or immortalized epithelial cell lines from the bladder or kidney are seeded 
and then infected with a pathogen under static conditions (123). Although cell culture models 
have generated a wealth of molecular data to understand the host-pathogen interactions on the 
renal epithelium (124–128), they cannot mimic the in vivo complexity. The flow of the 
primary filtrate constantly challenges bacteria in the kidney; it is a balancing act between 
adhesion and discharge rather than a mere deposition of bacteria on cells as in the static 
environment of a well plate. Host- and bacteria-secreted factors are fluctuating rather than 
accumulating statically, acting locally, as well as distally, as they are transported by the 
filtrate flow. Moreover, cells face a primary filtrate that is continuously renewed and not 
saturated by bacterial and host metabolic byproducts as in well plates. Finally, the crucial 
parameter of shear stress, which affects renal cell’s physiology and bacterial adhesion 
organelles, is absent (129–134). 
Based on advances in fluidics and microengineering, a new category of in vitro cell culture 
models was developed, called organ-on-a-chip, which recapitulates organ- and tissue-level 
structure and physiology (135). Typically, organ-on-a-chip is based on devices with hollow 
microchannels seeded with cells and perfused with culture medium.  Depending on the 
number and arrangement of microchannels, organ-on-a-chip can accommodate a single tissue 
or tissue interfaces. The chip format offers several advantages for a controlled, 
physiologically relevant in vitro model. Sensors, fluid flow, porous substrates and mechanical 
strain can be integrated to mimic organ function (120).  Fabrication with clear materials, such 
as polydimethylsiloxane, plastic, and glass, enables real-time monitoring on-chip with 
microscopy (120). Currently, organ-on-a-chip models for several organs and tissues have 
been developed, such as the liver (136–140), kidney (141–145) lung (146, 147), intestine 
(148, 149) and blood-brain-barrier (150, 151).  
Considering all the advantages mentioned above, organ-on-a-chip would be an ideal model to 
study host-pathogen interactions under spatiotemporal, single-cell resolution. However, the 
use of organ-on-a-chip models for infection studies is still at an early stage. In a proof-of-
concept study, neutrophil transmigration and phagocytosis of E. coli have been shown in a 
lung-on-a-chip containing an interface of endothelial and alveolar epithelial cells (147). In a 
gut-on-a-chip model, co-culture of intestinal epithelial cells with an intestinal flora microbe 
has been achieved (148). Bacterial adhesion of Neisseria meningitidis and Staphylococcus 
aureus to endothelial cells (152–154), as well as bladder cell invasion by UPEC (155), under 
shear stress conditions has also been explored. Microbiologists have only just unlocked the 
possibilities of organ-on-a-chip for infection studies. Further development of the field can 
lead to a better understanding of bacterial pathogenesis. 
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1.4.2 Phenotypic screening platforms in microbiology 
Advances in genomic technologies refined our view of bacterial pathogenesis with the 
discovery of several new genes. Together with this explosion of genomic information, came a 
need for high-throughput and quantitative methods for genotypic and phenotypic screening of 
bacteria (156, 157). Despite these needs, platforms such as the agar plate and the 96-well 
plates remain a staple in microbiology.  
Development of the agar plate in the 1880s was instrumental in establishing causality 
between pathogen and disease (158, 159); it enabled isolation and in vitro culture of bacteria 
from the diseased host. Today, it is considered a low-throughput platform, which generates 
mainly qualitative data. One major limitation is the incompatibility with spectrophotometry 
and microscopy. For instance, bacteria with gene mutations affecting catalytic activity can be 
screened only qualitatively using chromogenic or fluorogenic substrates (160). Furthermore, 
growth is assessed at the incubation endpoint, because bacteria have to grow long enough to 
be visible on the macroscale. At the endpoint, only composite growth is evaluated, whereas 
little is revealed about gene mutations that could affect the parameters of growth rate, growth 
efficiency, and growth lag (161–163).  
The shift to liquid cultures in 96- and 384-well plates improved throughput and enabled 
quantitative phenotypic screening with spectrophotometry. At the same time, the large 
number of wells in these formats is followed by a more laborious and time-consuming sample 
loading that often requires automation to be robust. Moreover, well dimensions are not 
optimal for single-cell analysis (164), especially when it comes to microscopic analysis.  
An alternative to 96- and 384-well plates is the use of microfabricated devices. Several 
applications have already taken advantage of such devices to culture bacteria that had been 
uncultivable in traditional platforms and to discover new antimicrobial compounds (165, 
166), study bacterial behavior on a single-cell level (167–169), and improve molecular 
methods in microbiology (170). By delivering new physical techniques, microfabrication has 
the potential to address the need for high-throughput and high-resolution quantitative 
screening in microbiology, but also improve bacterial cultivation (121, 122).   
1.4.3 Microfabrication in antibiotic susceptibility testing 
Miniaturization in clinical microbiology has the potential to improve phenotypic AST. The 
clinically validated automated instruments VITEK2 and Accelerate PhenoTM have already 
incorporated microfluidics into their system to facilitate sample loading and processing (101, 
110). Several other AST methods under pre-clinical development have combined 
microfluidics or miniaturized arrays with microscopy to determine antibiotic resistance 
between 2 - 6 h, either directly from a clinical sample or using a pure bacterial inoculum 
(Table 1) (95, 171–175). Although some devices feature dozens or hundreds of miniaturized 
compartments, the AST throughput remains low (Table 1) (95, 171, 172). The presence of 
only one loading inlet limits these devices to test one sample against one antibiotic 
concentration at a time. Without the possibility to accommodate 2-fold serial antibiotic 
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dilutions, a MIC cannot be determined, and therefore results are only qualitative. Besides the 
microfluidic design, the microscopy-based diagnosis itself limits throughput, as it is time-
consuming and computationally intense for a high-throughput setting (173). So far only one 
of these devices, based on a 96-well plate format, features dedicated inlets for each 
microchannel at the bottom of the wells, which enables up to 96 sample-antibiotic 
combinations (173). However, loading of the samples is laborious; bacteria mixed with 
agarose are pipetted in each microchannel and after solidification, each antibiotic 
concentration has to be added separately. Moreover, microscopy-based detection required 
20 - 30 min per sample. 
Recently, a microfluidic device was combined with nucleic acid quantification to determine 
antibiotic susceptibility within 30 min (98). An infected urine sample was mixed with culture 
broth and incubated for 15 min, before proceeding with digital PCR in a microfluidic device 
with 1280 wells. However, similar to the other AST methods described, this device contains 
only one loading inlet. This limits the throughput to testing one sample against one antibiotic 
concentration per device at a time, and therefore a MIC cannot be determined. Moreover, 
sample preparation for this method is rather laborious, as it includes several steps, such as 
heat treatments, DNA extraction, and DNA concentration adjustment.  
The short turnaround times reported in these microfluidic AST methods are often based on 
either a few bacterial strains or a limited number of antibiotics (Table 1) (95, 98, 171, 172, 
174). Testing with an extended number of strain-antibiotic combinations would most likely 
reveal a considerable variability in turnaround time, considering the heterogeneity among 
bacteria, as well as the different mode of action of each antibiotic. Considering the 
advantages and disadvantages of these studies, future efforts should focus on the 
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2 AIMS 
Advances in the field of microfabrication and organic chemistry can revolutionize the study 
of bacterial pathogenesis and address unmet needs in clinical diagnostics. In my thesis, I 
worked at the intersection of microbiology, miniaturized devices, and optical probes to: 
1. Develop a rapid and high-throughput AST method 
2. Establish a high-resolution phenotypic screening platform for bacteria 
3. Delineate UPEC pathogenesis in pyelonephritis with a temporal and single-cell 
resolution by simulating the proximal tubule physiology in vitro  
4. Develop a diagnostic method for biofilm-associated UTI based on the detection of 
cellulose as a biofilm marker  
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3 RESULTS AND DISCUSSION 
3.1 THE NANOWELL SLIDE AS A NEW PLATFORM FOR MICROBIOLOGY 
Papers I-III describe the development of clinical and research applications for microbiology 
using a nanotiter well plate. This miniaturized plate called the nanowell slide (nwSlide), 
features 672 nanotiter wells (nanowells) within the dimensions of a microscope slide 
(25 x 75 mm) (Fig. 3A, B) (176). It comprises a 500-µm thick silicon grid anodically bonded 
to a 175-µm thick glass slide (Fig. 3C). This grid is designed in an array of 
14 rows x 48 columns, which forms the 672 nanowells when bonded to the glass slide. Each 
nanowell has outward-tilted walls with a surface area of 650 x 650 µm2 at the bottom and 
1360 x 1360 µm2 at the top, generating a 500-nl volume capacity per nanowell (Fig. 3C). The 
design and material of the nwSlide offer several advantages for microbiology. The glass 
bottom and slide dimensions allow for high-resolution microscopy. The inter-well distance is 
small enough to maximize the nanowell density on the slide but at the same time compatible 
with mainstream lab instrumentation, such as fluorescence activated cell sorting (FACS) and 
spectrophotometry (177). The nanowell volume capacity of 500 nl dramatically decreases 
reagent consumption down to ≈336 µl. In contrast to other high-throughput well plates, where 
automated liquid handling is needed due to their considerable well height, the 675-µm 
thickness of the nwSlide enables manual loading in a single pipetting step. In papers I-III we 
leveraged the versatility of the nwSlide to develop a rapid, high-throughput AST and a 
multiparametric phenotypic screening platform for bacterial mutants. 
3.2 PAPER I: DEVELOPMENT OF A RAPID ANTIBIOTIC SUSCEPTIBILITY 
TESTING METHOD ON THE NANOWELL SLIDE  
Paper I reports our first steps in transforming the nwSlide into a nanowell AST method 
(nwAST). First, we designed and tested the procedures for antibiotic coating and bacterial 
sample loading. We coated the nwSlide with seven 2-fold serial dilutions of ampicillin, 
spanning a clinically relevant range between 0.5 – 32 µg/ml (Fig 3D). To allow for technical 
replicates, which are usually absent in clinical AST, each dilution was coated in 35 
nanowells. To evaluate the quality of each test, 2 areas were designated to control for reagent 
contamination (negative control) and sample loading (positive control). The slim design of 
the nwSlide enabled us to easily load bacterial samples by smearing. The nwSlide was then 
sealed with a gas permeable PDMS membrane. To enable detection of growth during 
incubation at 37°C, we applied absorbance recordings. We adapted the nwSlide for use with a 
well plate spectrophotometer by fitting it in a custom 3D-printed adapter with the dimensions 
of a 96-well plate (Fig. 3E). By introducing all these adjustments, the nwSlide was 
transformed into a phenotypic nwAST. 
We evaluated technical performance by inoculating the nwAST with 1 x 105 cfu/ml 
(50 cfu/nanowell) of the reference E. coli strain ATCC 25922. While incubating the nwAST 
in the spectrophotometer at 37°C, we measured absorbance every 10 min for 10 h. Because of 





Fig. 3 Illustration of the nwAST. (A) Top view of the nwSlide and (B) a close-up of individual nanowells. (C) Side view 
of a nanowell with antibiotic coating (orange). (D) Layout of the nwAST functionalized with a 2-fold serial dilution of 
ampicillin between 0.5 – 32 µg/ml. Each dilution was coated in 35 nanowells. A positive (antibiotic-free) and negative 
(32 µg/ml ampicillin) control was included. (E) The custom 3-D printed adapter makes the nwSlide compatible with a well 
plate spectrophotometer. Dashed lines indicate the position of the nwSlide in the adapter. Screws (purple) lock the nwSlide in 
place. A waterbath (W) is included to prevent evaporation in the nwSlide. (Figure reprinted from Weibull E. et al., 2014). 
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measurements as growth curves would be a daunting task. Instead, we chose heatmaps to 
present a clear overview of bacterial growth under different antibiotic concentrations. 
Examination of the heatmap showed that growth was inhibited at ≥ 8 µg/ml of ampicillin, 
defining this concentration as the MIC. This result was in agreement with Etest and 
microbroth dilution assays, as well as the Clinical & Laboratory Standards Institute 
guidelines (178). We concluded that antibiotic coating, sample loading, and adjustment to the 
3D-printed adapter were optimally performed, demonstrating the suitability of the nwSlide 
for AST. 
Guidelines for the interpretation of antibiotic susceptibility results are based on a standardized 
bacterial inoculum of 1-5 x 105 cfu/ml. This requires the isolation and subculture of bacteria 
from a patient sample before performing AST. To investigate whether the nwAST generates 
accurate results when the inoculum deviates from the guideline recommendations, we tested 
1 x 104 cfu/ml (5 cfu/nanowell) and 1 x 106 cfu/ml (500 cfu/nanowell) of ATCC 25922 
against ampicillin. We determined a MIC of 8 µg/ml regardless of the inoculum 
concentration. Therefore, we could accurately determine susceptibility even when there was a 
10-fold deviation from the standard inoculum. This showed the potential for directly applying 
bacteria isolated from patient samples on the nwAST. Further investigation is needed as 
different inoculum concentrations, especially > 1 x 105 cfu/ml, can affect the MIC for several 
antibiotics (179)(180).  
It became evident from heatmaps that absorbance-based detection could differentiate between 
resistant and susceptible bacteria before the incubation endpoint of 10 h. Thus, we 
implemented an algorithm that identifies the time point (Tlag) when bacteria transition from 
lag to log phase. This algorithm processes absorbance measurements preceding and following 
the time point in question and determines whether absorbance has increased. If this increase 
exceeds a predefined threshold, this is interpreted as bacterial growth. We applied the Tlag 
algorithm on absorbance recordings from the nwAST of ATCC 25922 against ampicillin. 
Depending on the inoculum concentration, a Tlag ≈ 1 - 4 h was found for ≤ 4 µg/ml 
ampicillin, whereas no Tlag was generated for ≥ 8 µg/ml ampicillin. Thus, the Tlag 
differentiated between inhibited and non-inhibited bacteria and determined a MIC = 8 µg/ml, 
which was in agreement with the analysis at the incubation endpoint. To verify the accuracy 
of Tlag, we examined bacteria in each nanowell by microscopy. We found that the Tlag 
algorithm was 98.3 % accurate, with only a few false positive and false negative nanowells 
for bacterial growth. Importantly, the technical replicates of the positive controls generated 
similar Tlag values, which showed that bacteria were evenly loaded on the nanowells. Because 
the algorithm's calculations require absorbance data from time points following the time point 
in question, the total turnaround time is 2 h longer than the Tlag calculated value. Thus, the 
MIC determination time for ATCC 25922 would be 3-6 h, depending on the inoculum 
concentration. Considering that conventional AST delivers results at 18 h, the Tlag algorithm 
shortened the turnaround time by 3-6 times. 
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Ideally, the nwAST should feature multiple antibiotics without the risk of cross-
contamination between nanowells. To that end, we coated the nwSlide with 3 different 
antibiotics in adjacent areas. We added 2 concentrations from each antibiotic, one above and 
one below the clinical breakpoint. Testing of ATCC 25922 showed that the nwAST 
accurately determined the susceptibility pattern for 3 antibiotics simultaneously within 4 h 
10 min, without any signs of cross-contamination. 
After optimizing the parameters of nwAST with ATCC 25922, we tested whether antibiotic 
susceptibility could be determined using clinical UPEC isolates. For this purpose, we coated 
the nwSlide with 2-fold serial dilutions of ciprofloxacin and cefotaxime and loaded the 
nanowells with 3 clinical UPEC strains on separate slides. To reduce the turnaround time of 
the Tlag algorithm, absorbance was measured every 5 instead of 10 min. nwAST results were 
in agreement with Etest and VITEK2 for all 3 strains, with a turnaround time of ≈ 3-4 h. 
Collectively these results showed that the nwAST delivers accurate results for clinical strains 
up to 6 times faster compared to other clinically established AST methods. 
3.3 PAPER II: CLINICAL ADAPTATION AND VALIDATION OF THE 
NANOWELL ANTIBIOTIC SUSCEPTIBILITY TESTING METHOD 
In Paper II we adapted the nwAST to meet clinical requirements for UPEC testing. The 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends that 
AST for E. coli should be performed under aerobic conditions. We investigated the culture 
conditions in sealed nanowells by culturing E. coli WT and ∆fnr, a mutant with impaired 
growth under anaerobic conditions. This mutant exhibited a similar growth rate and culture 
density as the WT strain, showing that the nanowell microenvironment is aerobic for at least 
16 h.  
UPEC is routinely tested against 6 antibiotics at Karolinska University Hospital: ampicillin, 
ciprofloxacin, cefadroxil, mecillinam, nitrofurantoin, and trimethoprim. We aimed to design 
the nwAST so that a MIC is determined for all 6 antibiotics. MIC determination can help 
clinicians to optimize antibiotic therapy (181). Moreover, it offers better surveillance of the 
infection-causing pathogen, as antibiotic treatment could still fail against susceptible bacteria 
that have a MIC close to the clinical breakpoint (182). Therefore, we coated the nwSlide with 
seven 2-fold serial dilutions for each antibiotic, 2 above and 5 below the clinical breakpoint 
(Fig. 4). Each dilution was coated in 4 nanowells to control for technical reproducibility.  
We evaluated clinical performance with 70 UPEC clinical isolates, using agar disc diffusion 
assays as the reference method. The overall categorical agreement was 97.9 %, which 
surpassed the minimum FDA requirement of 90% (183). Major errors ranged between 
0 - 8.3 % depending on the antibiotic, whereas no very major errors were detected. Overall, 
these results showed an excellent clinical performance for the nwAST when compared to 
agar disc diffusion. 
The bacterial lag phase can range from one to several hours depending on the antibiotic-strain 
combination (184, 185). The large number of tested UPEC gave us an excellent opportunity
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Fig. 4 nwAST layout for UTI. The nwSlide was coated with 6 antibiotics: ampicillin (AMP), ciprofloxacin (CIP), 
nitrofurantoin (NIT), cefadroxil (CFR), mecillinam (MEC), and trimethoprim (TMP). Seven concentrations, in 4 technical 
replicates each, were added from each antibiotic. Negative (NEG, medium only) and positive (POS, medium + bacteria) 
control areas of 24 nanowells each were also included. (Figure modified and reprinted from Veses-Garcia M. et al., 2018) 
to investigate the impact of bacterial heterogeneity on diagnostic turnaround time. For 
resistant strains, application of the Tlag algorithm showed that Tlag ranged between 
1 h 40 min - 6 h 10 min. This corresponded to an overall turnaround time of 3 h 40 min –
 8 h 10 min. For susceptible strains, Tlag ranged between 1 h 30 min - 10 h, which 
corresponded to an overall turnaround time of 3 h 30 min - 12 h. These broad ranges of 
turnaround times reflected the biological variability of different UPEC strains. The finding 
that resistant bacteria transition from lag to log phase as late as 6 h 10 min post-inoculation 
stresses the importance of adequately incubating a sample before determining susceptibility. 
An incubation time shorter than a strain’s lag phase could generate a very major error by 
misidentifying a resistant strain as susceptible. Contrary to other studies that set a predefined 
incubation time based on findings from a few strain-antibiotic combinations, our study 
highlights the advantage of using an algorithm that adapts on bacteria’s lag phase. 
A prolonged lag phase can delay absorbance-based detection of bacterial growth and 
consequently the AST turnaround time. To circumvent this type of delay, we took advantage 
of the nwAST’s compatibility with microscopy. Depending on their mode of action, 
antibiotics can affect bacterial morphology (186–190). To investigate whether we can 
determine their susceptibility based on morphology, we tested 2 UPEC strains incubated 
against the 6-antibiotic panel in the nwAST. After 3 h of incubation, we captured images of 
their morphology for each antibiotic concentration. We performed morphotyping analysis on 
the captured images by analyzing 3 different bacterial shape parameters: major/minor axis 
ratio, perimeter, and circularity. Strains susceptible to antibiotics deviated from the typical 
rod-shaped morphology of E. coli, forming filaments or exhibiting swelling. In contrast, 
resistant strains retained the rod-shaped morphology. This proof-of-concept investigation 
showed that microscopy could potentially resolve delayed diagnosis and indicate whether the 
lack of Tlag in a sample is due to true susceptibility or a prolonged lag phase. 
3.4 PAPER III: THE NANOWELL SLIDE AS A PLATFORM FOR 
MULTIPARAMETRIC PHENOTYPIC SCREENING OF BACTERIA 
In Paper III we developed the nwSlide into a phenotypic screening platform for rapid 
identification of growth-, metabolism-, and morphology-associated mutations in bacteria 
(Fig. 5). Isolation of single bacterial colonies by streaking on agar plates is a prerequisite for 
all downstream analyses in microbiology. We exchanged the agar plate for the nwSlide and 
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developed a FACS-based workflow to deposit single-bacteria in each nanowell with a 
labeling-free gating strategy. We evaluated this strategy by sorting a mixture of 3 flagellar 
mutants (∆fliD, ∆fliS, ∆fliT) at a 1:1:1 ratio on the nwSlide. Bacteria were incubated and then 
retrieved with needles through the soft penetrable membrane of the nwSlide for downstream 
subculturing and mutant identification. Screening of subcultured bacteria with PCR showed a 
single-mutant relative frequency of 82.8 ± 7 %. Thus, we successfully obtained monoclonal 
cultures in the majority of the nanowells. 
Algorithm-assisted analysis of absorbance measurements in Paper I & II enabled us to 
quickly and accurately identify nanowells with growing bacteria and determine their lag 
phase duration (Tlag). In Paper III we improved algorithm-assisted analysis by developing a 
3-checkpoint algorithm, which we termed nanoculture Optical Signal Analysis Tool 
(nOSAT). These 3 checkpoints control: i) whether a nanowell culture generated a Tlag, 
(ii) whether it reached maximum optical density (ODmax) ≈ 0.006 – 0.075, and (iii) whether it 
exceeded growth efficiency ≥ 0.006. When absorbance measurements meet all 3 checkpoints, 
a nanowell is designated as a successfully grown bacterial culture. We evaluated nOSAT by 
processing absorbance measurements from cultures deriving from single-sorted bacteria on 
the nwSlide. Comparison of nOSAT with growth detection by microscopy showed 95.24 % 
sensitivity and 98.77 % specificity in identifying nanowells with bacterial growth. The few 
false negatives that affected sensitivity were due to bacterial growth levels below the 
detection limit of spectrophotometry. In rare cases, empty nanowells with absorbance 
fluctuations were designated as positive for bacterial growth, which accounts for the small 
number of false positives affecting specificity. Overall, we developed a robust algorithm that 
copes with absorbance artifacts, identifies bacterial growth, as well as determines the lag 
phase duration and growth efficiency in nanowells. 
Phenotypic screening of bacteria usually requires initial selection of monoclonal colonies on 
agar plates, which are then analyzed by subculturing in microtiter plates containing 
colorimetric or fluorogenic substrates. We aimed to develop a one-step phenotypic screening 
workflow. As a proof-of-concept, we designed an assay to discriminate between E. coli 
bacteria with a positive or negative β-galactosidase phenotype. This assay was based on 
fluorescence emitted by the substrate 4-Methylumbelliferyl β-D-galactopyranoside (MUG) as 
it becomes hydrolyzed by β-galactosidase. First, we incubated separate cultures for WT and 
∆lacZ bacteria on nwSlides loaded with MUG. We recorded fluorescence at the incubation 
endpoint to establish the fluorescence discrimination threshold between WT and ∆lacZ. To 
test the assay’s feasibility, we added ∆lacZ in WT bacterial samples at a representation of 0.2, 
2 and 20 % and single-sorted the mixed samples on nwSlides loaded with MUG. We were 
able to phenotypically identify ∆lacZ in the nwSlide with an accuracy ranging from 
87.12-100 %, depending on its representation in the sample. These results demonstrated that 
our assay could detect a phenotype of interest down to 0.2 % representation in a sample in a 
one-step workflow. 
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Fig. 5. A platform for multiparametric phenotypic screening of bacterial mutants on the nwSlide. (A) E. coli was 
electroporated with the TnMHA transposon, which encodes a kanamycin resistance gene and GFP. Bacteria successfully 
integrating TnMHA were selected based on GFP fluorescence with FACS and single-sorted on the nwSlide. (B) Single-sorted 
mutants were incubated and monitored with kinetic absorbance measurements (dotted arrows) for 16 h. Absorbance data were 
processed with nOSAT to determine the bacterial growth profile in each nanowell. Microscopy was applied to identify 
mutants deviating from normal morphology. (C) Based on growth and morphological profiles, mutants with phenotypes of 
interest were retrieved and subcultured for genotype analysis. The transposon insertion site was mapped using a cloning-free 
screening, comprising a single-primer PCR and sequencing. (Figure reprinted from Antypas H. et al., 2018). 
Another microbiology application that could be benefited from the combination of the 
nwSlide with FACS is transposon mutagenesis. Therefore, we developed a one-step 
workflow to directly select and phenotypically screen transposon mutants. To take advantage 
of FACS, we constructed the transposon TnMHA, which encodes the green fluorescent 
protein (GFP) and kanamycin resistance (Fig. 5A). To evaluate whether FACS discriminates 
between WT and TnMHA mutants, we electroporated E. coli with TnMHA and then 
analyzed bacteria for GFP fluorescence in the sorter. Analysis showed a GFP-fluorescent 
subpopulation of bacteria, demonstrating that bacteria successfully integrated and expressed 
TnMHA. GFP-positive bacteria were single-sorted on a nwSlide loaded with medium 
containing kanamycin. In this second selection step, kanamycin prevented growth of WT 
bacteria that were falsely sorted on the nwSlide. After 16 h incubation with kinetic 
absorbance measurements, nOSAT identified 371 nanowells with successfully grown 
transposon mutants (Fig. 5B). 
Transposons are inserted at random locations in the bacterial chromosome. Gene disruption 
can lead to an altered phenotype, which could help us understand gene function. Using 
nOSAT, we identified transposon mutants deviating from the median lag phase duration and 
growth efficiency. By applying microscopy, we identified a mutant forming clumps of tightly 
aggregated bacteria and another mutant forming highly irregular aggregates. To map the 
transposon insertion sites in these mutants, bacteria were retrieved from the nwSlide and 
screened using a cloning-free procedure, based on single-primer PCR and sequencing 
(Fig. 5C). Thus, by employing this workflow, a rapid first link between gene and phenotype 
was established.  
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3.5 PAPER IV: INVESTIGATION OF UROPATHOGENIC ESCHERICHIA COLI 
COLONIZATION UNDER SHEAR STRESS USING A RENAL PROXIMAL 
TUBULE-ON-A-CHIP 
In paper IV, we developed a physiologically relevant in vitro model to investigate UPEC 
colonization in pyelonephritis. Using microfluidic channels seeded with human renal 
epithelial cells, we studied bacterial pathogenesis under shear stress (Fig. 6). In this model, 
named proximal tubule-on-a-chip (PToC), we mimicked the shear stress of the S1 segment of 
the proximal convoluted tubule (Fig. 6A) because it would enable to compare our results with 
previous findings from intravital imaging of the S1 segment in rats (42). By placing PToC 
inside a portable 37°C incubator on the microscope stage, we were able to monitor the 
infection with a full temporal resolution by performing time-lapse microscopy (Fig. 6B).  
Bacterial adhesion to renal epithelial cells is essential for the establishment of pyelonephritis. 
To study adhesion, we cultured UPEC CFT073, a pyelonephritic isolate, in cell culture 
medium until exponential phase. Yeast and blood agglutination showed that bacteria were 
expressing both P and Type 1 fimbriae under these conditions.  By introducing CFT073 in 
PToC, the bulk of bacteria were rapidly expelled, with only a few resisting the flow. To 
analyze these events in more detail, we performed single-cell trajectory analysis (SCTA) on 
time-lapse microscopy videos recorded in the PToC. With this analysis, we tracked single 
bacteria in our microscopic field of view during the first 8 s of infection to characterize their 
displacement by the flow. SCTA identified 3 displacement patterns: 1) linear displacement 
with a mean velocity > 30 µm/s, 2) linear displacement with a mean velocity < 30 µm/s, 3) 
non-linear displacement with a mean velocity < 30 µm/s. In pattern 1, displacement was 
mainly dictated by the flow, and therefore bacteria were designated as unbound. In contrast, 
bacteria exhibiting patterns 2 and 3 were resisting the flow. We designated these bacteria as 
rolling and bound respectively. Although not completely immobilized on renal cells, rolling 
bacteria were displaced at a much slower velocity compared to unbound bacteria, suggesting 
that they had established weak interactions with renal cells. Bound bacteria were relatively 
few. They were immobilized on renal cells either briefly (< 8 s) or throughout the 8-s time-
lapse video. This suggested that a minority of bacteria expressed the fimbrial profile required 
for initial adhesion to renal cells under shear stress. 
To understand how CFT073 expands on renal cells under shear stress, we followed bacteria 
with SCTA throughout the first hour of infection. We observed an equal number of 
attachment and detachment events that resulted in a rapid turnover of adherent bacteria. 
Binding duration for the majority of bacteria was 1-2 min (50.2 ±11.9 %) and 2.5-30 min 
(42.8 ± 8.2 %). A minority (7 ± 4.8 %), however, was able to remain stably attached for 
longer than 30 min. We designated these bacteria as the founder population of infection. To 
investigate the role of fimbriae in initial adhesion, we constructed an isogenic CFT073 
∆papG mutant. Binding duration was significantly reduced in the absence of PapG, with 
85 ± 1.6 % of ∆papG bacteria adhering for 1-2 min and 12 ± 4.7 % for 2.5 -30 min. Long-
term adhesion of ∆papG, however, was not significantly different compared to WT, with
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Fig. 6 Simulation of the renal proximal tubule environment in vitro. (A) Illustration of a nephron. Blood filtration in the 
glomerulus (G) generates the primary filtrate, which enters the Bowman’s capsule (BC) and flows through the S1 segment of 
the proximal convoluted tubule (grey shade). Exposure of the renal epithelial cells to the primary filtrate flow generates shear 
stress on their surface. Arrow = primary filtrate flow direction. (B) Illustration of the PToC setup. CO2-independent medium 
pumped at a flow rate of 75 µl/min enters a microchannel seeded with A498 renal cells, simulating the shear stress in the S1 
segment of the proximal tubule. The slide with the microchannels is placed on the microscope stage inside a portable 
incubator at 37°C. Bacteria are injected in the microchannel via the inlet and infection is followed with phase-contrast time-
lapse microscopy.  
3 ± 3.9 % adhering for longer than 30 min. Overall, PapG prolonged binding duration, but it 
was not essential for long-term adhesion. 
We monitored the founder population of bacteria with time-lapse microscopy to understand 
how these few bacteria develop into an infection. Shortly after adhering to renal cells, several 
bacteria multiplied with a generation time of ≈ 20 min. Rapid division was crucial for 
overcoming detachment due to shear stress. Bacteria bound for longer than 20 min had 
sufficient time to divide and further establish UPEC’s presence on renal cells in 2 ways. After 
each division, daughter cells released into the microchannel helped to spread the infection, 
whereas daughter cells remaining attached formed aggregates. These aggregates gave rise to 
microcolonies, which presented UPEC with several advantages. Firstly, microcolonies 
enabled bacteria to expand beyond the cell surface and form 3-dimensional microcolonies. In 
the in vivo situation, the ability to extend towards the lumen of the proximal tubule would 
confer a significant colonization advantage. Secondly, bacteria in microcolonies continued to 
proliferate rapidly, contributing to the microcolony size and infection spread by releasing an 
even higher number of bacteria. Thirdly, microcolonies showed increased resistance to shear 
stress and remained bound for several hours. These findings demonstrated how the transition 
from a single-cell to microcolony lifestyle consolidated UPEC’s presence on renal cells under 
shear stress. 
When we followed infection with an isogenic ∆fimH mutant of CFT073 in PToC, we 
observed that bacteria also multiplied rapidly, but expanded almost exclusively as a single 
layer in direct adhesion to renal cells, whereas the ability to form microcolonies was severely 
impaired. This suggested that FimH is involved in interbacterial interactions in 
pyelonephritis, which might be mediated by binding to mannose residues of LPS (48). 
Further investigations, however, are needed to show whether the mannose-binding lectin 
domain of FimH is involved.  
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PapG and FimH enhanced the ability of UPEC to colonize renal cells under shear stress. 
Therefore, we investigated their role in the infection outcome. CFT073 WT was expressing 
both adhesins, and it was able to colonize renal cells and trigger cell rounding at ≈ 2.5 h. In 
contrast, the adhesin mutants required more time to colonize host cells, with ∆papG 
triggering host cell rounding after 3.5 h and ∆fimH after 4 h. These findings showed that the 
onset of host-cell rounding is proportionate to the bacterial load present on renal cells and that 
it is triggered regardless of the PapG and FimH presence. Despite PapG and FimH enhancing 
colonization, they were not a prerequisite to establish an infection. We concluded that UPEC 
harbors a broad repertoire of redundant fitness and virulence determinants to establish an 
infection under shear stress in a PapG- and FimH-independent manner. Contrary to static in 
vitro cell cultures, PToC delineated UPEC colonization with a single-cell temporal resolution 
under shear stress conditions.  
3.6 PAPER V: DETECTION OF CELLULOSE IN URINE AS A BIOMARKER 
FOR BIOFILM-ASSOCIATED URINARY TRACT INFECTIONS 
In Paper V, we investigated whether UTI can be biofilm-associated. Cellulose is an ECM 
component of UPEC biofilm, which is not naturally produced by the human host. Therefore, 
we aimed to screen urine from UTI patients for the presence of cellulose as a biomarker for 
biofilm-associated UTI. To that end, we set up a novel method named cellulose optotracing, 
based on the LCO h-FTAA (Fig 7A). In this method, a sample is incubated with h-FTAA for 
15 min and then excited using a spectrophotometer between 300-520 nm with emission 
collected at 545 nm. If there is cellulose in the sample, h-FTAA changes its conformation 
upon binding to cellulose and generates a cellulose-specific fluorescence spectrum with a 
primary excitation peak at 464 nm and a secondary at 488 nm.  
Cellulose forms a mesh with other proteins and polysaccharides in the ECM of UPEC biofilm 
(191). To investigate whether optotracing detects cellulose in its native complexity, we 
screened biofilm from UPEC No12, which is a UTI isolate characterized as a cellulose 
producer based on its morphotype on Congo red agar plates (70). Optotracing generated an 
excitation spectrum with a primary excitation peak at 464 nm and a secondary at 488 nm 
(Fig. 7B, red line). In contrast, cellulose optotracing of UPEC No12 ∆bcsA, an isogenic 
mutant of the cellulose synthase catalytic subunit, generated a spectrum lacking these 2 
excitation peaks (Fig. 7B, blue line). These results defined the 464- and 488-nm peaks as a 
cellulose-specific spectral signature and showed that optotracing detects cellulose in the 
complex ECM of UPEC, without interference from other biofilm components.  
Ideally, cellulose detection should be performed directly in urine. To characterize urine as a 
potential matrix for cellulose optotracing, we first characterized urine's native fluorescence. 
We excited urine samples from 8 healthy volunteers between 300-520 nm and collected 
emission at 545 nm, the same wavelength settings used in cellulose optotracing.  Our results 
showed that urine has strong fluorescence across all wavelengths, with excitation peaks 
between 360 - 380 nm. Moreover, the amplitude of fluorescence greatly varied among 
different samples. We then investigated whether urine’s native fluorescence interferes with
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Fig. 7 Cellulose optotracing in UPEC biofilms. (A) Structure of h-FTAA. (B) Normalized excitation spectra of cellulose 
optotracing in WT (red) and ∆bcsA (blue) biofilms of UPEC No 12 suspended in PBS. Average normalized fluorescence 
from n = 3 is shown. Black line = PBS + h-FTAA; Dotted vertical lines indicate the 464- and 488-nm peaks of the cellulose 
spectral signature. 
cellulose optotracing. We spiked 8 healthy urine samples with the same amount of purified 
cellulose and subjected them to optotracing. Although a clear cellulose-specific spectral 
signature was generated from 2 samples, urine’s fluorescence dominated over the cellulose 
signature in the other 6 samples. We concluded that cellulose optotracing directly in urine is 
feasible, but the variability of urine among different individuals can affect the reproducibility 
of the method and generate false negative results. 
Reproducibility is essential in an assay intended for clinical use. As urine was not a suitable 
matrix for optotracing, we replaced it with PBS. We initially spiked a healthy urine sample 
with WT and ∆bcsA UPEC biofilm and performed optotracing. Despite containing cellulose, 
the WT biofilm generated a negative result, with a similar spectral signature to ∆bcsA biofilm 
and to a non-spiked urine sample. To remove urine but keep biofilm components, we 
centrifuged all samples and resuspended them in PBS. Optotracing in PBS generated a 
cellulose signature for the WT sample, clearly differentiating it from the ∆bcsA biofilm and 
the non-spiked urine sample. Thus, this rapid and simple processing step removed any 
interference from urine and enabled us to detect cellulose. 
Having established a workflow to process urine for cellulose optotracing, we next applied our 
method on urine samples from 182 UTI patients and 8 healthy volunteers. To facilitate 
analysis of the 190 spectra generated with cellulose optotracing, we applied Principal 
Component Analysis and k-means clustering. To help us classify the clusters as 
cellulose-positive and cellulose-negative, optotracing spectra from WT and ∆bcsA biofilm 
preparations were also included as references for the analysis. We identified 27 UTI samples 
that clustered together with the WT biofilm. Thus, we designated them as cellulose-positive. 
We found 83 UTI samples that clustered together with the ∆bcsA biofilm, thus defining them 
as cellulose-negative. Although these samples lacked cellulose, we cannot exclude the 
presence of biofilm with a different ECM composition. Interestingly, samples from healthy 
volunteers were located in the periphery of the cellulose-negative cluster. This showed that 
optotracing might also have the potential to differentiate healthy from UTI urine samples. 
Moreover, this showed that low amounts of bacterial contamination from other species in 
healthy urine did not produce false positive results. The remaining 72 UTI urine samples 
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belonged to a third cluster between the cellulose-positive and cellulose-negative clusters. The 
spectral information of these samples was insufficient for classification. Although their 
spectra were distinct from the ones in the cellulose-negative cluster, they did not feature a 
cellulose spectral signature. Whether these spectra were compromised by the presence of host 
components present in UTI urine samples, it remains to be investigated. Overall, we 
demonstrated direct detection of native cellulose for the first time in urine samples, providing 
solid evidence that UTI can be biofilm-associated. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
4.1 PAPERS I-III: REINVENTING MICROBIOLOGY ASSAYS WITH THE 
NANOWELL SLIDE  
By replacing the agar plate and standard well plates with the nwSlide, we delivered 
high-throughput, user-friendly and versatile platforms for AST and phenotypic screening of 
bacteria. With dimensions equal to a microscopy slide, the nwSlide surpasses in throughput 
all other standard platforms, with a potential to screen up to 672 conditions simultaneously 
(Table 2). The possibility to include 4 technical replicates of 7 dilutions from 6 antibiotics 
enabled both MIC detection and technical reproducibility control. The full throughput 
potential of the nwAST has yet to be reached. Currently, we have functionalized 168 out of 
672 nanowells. With the help of automation in antibiotic coating procedures, the nwAST 
could further expand with the inclusion of additional antibiotics and reagents for pathogen 
identification. 
User-friendliness is a parameter often lacking in microfabricated devices. Easy inoculation of 
bacterial samples is one feature that made the agar plate handy for use in AST compared to 
the more laborious pipetting in 96- and 384-well plates. Although a multiwell device, the slim 
design of nwSlide enables one-step inoculation by smearing the sample across all nanowells 
(Table 2). Besides easy inoculation, retrieval of bacterial samples from nanowells is also 
feasible. When it comes to cost-affordability, the nwSlide consumes the least amount of 
reagents compared to the other platforms, and it can also be reused after autoclaving. 
The design of the nwSlide is compatible with mainstream technologies. Spectrophotometry 
and microscopy on the nwAST delivered results as early as 3 h. The compatibility of the 
nwSlide with FACS, spectrophotometry, and microscopy merged the steps of bacterial 
isolation, selection, subculturing and phenotypic screening into one and decreased hands-on 
time. Already from the first incubation round of single-sorted transposon mutants, phenotypic 
screening for growth- and morphology-associated mutations could take place. Growth 
screening of cultures starting with single bacteria is more robust in the ≥ 8 times smaller 
volume of nanowells compared to 96- and 384-well plates, as bacteria reach the absorbance 
detection limit of 1 x 107 cfu/ml faster (Table 2). Accordingly, the smaller bottom surface and 
height of the nanowells are more suitable for morphology analysis by microscopy. Overall, 
the applications developed on the nwSlide are easily scalable to different laboratory settings 
to serve basic, industrial and clinical research purposes. Potential future applications could 
include screening of clinical or environmental samples for pathogen surveillance or even 
isolation and characterization of new species. Beyond assay throughput, microbiologists need 
more than ever to run well-controlled experiments and export high-resolution quantitative and 
qualitative data. Our platform delivers high-resolution data without compromising 
throughput, and we foresee that microbiologists will eagerly use it for a wide range of 
applications. 
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	Table 2. Comparison of the nwSlide with standard microbiology platforms 
 
Microbiology platforms 
  Agar plate 96-well plate 384-well plate nwSlide 
Dimensions     
Length x width (mm) Ø 90 or 150  127.71 x 85.43 127.76 x 85.48 75 x 25 
Height (mm) 14.5 14.1 7.5 - 14.4 0.675 
Throughput1 1 96 384 672 
One-step inoculation Yes No No Yes 
Sample retrieval Yes Yes Yes Yes 
Reagent consumption (ml) 0.1 - 1 4.8 - 19.2 1.5 - 55.7 0.34 
Reusable No No No Yes (autoclavable) 
Single-cell sorting Yes Yes Yes Yes  
Quantitative growth 
screening − + + + + + + 
Morphological analysis − + + + + 
1 Number of conditions that can be tested simultaneously 
 
Key to rapid growth detection in the nwAST was the implementation of the Tlag algorithm on 
absorbance data. This algorithm detects the time point when bacteria transition from lag to 
log phase, rendering unnecessary to inspect a culture for bacterial growth at the incubation 
endpoint. Future integration of this algorithm into spectrophotometric analysis software will 
enable real-time detection of antibiotic resistance as soon as bacteria start to grow. 
Algorithm-based real-time detection is a faster and safer option contrary to assays with pre-
defined incubation time. It eliminates the long overnight incubation times, and at the same 
time, it adjusts to bacteria’s intrinsic physiology. Pre-defining a short incubation time entails 
the risk to misdiagnose resistant bacteria with an extended lag phase as susceptible. This was 
clearly demonstrated when UPEC generated Tlag values within a broad time range. Besides 
rapid growth detection, algorithm-assisted analysis facilitated the handling of a large amount 
of spectrophotometric data. By applying nOSAT, we detected nanowells with growth and 
identified differences in growth parameters rapidly, offering quantitative information from 
the first incubation round. 
We achieved a decrease in AST turnaround time from typically 18 h down to 3-6 h. Isolation 
and subculturing of bacteria from a patient sample to prepare the AST inoculum is yet 
another time-consuming step. Further development could focus on overriding this step and 
run the nwAST directly with a clinical sample. Different approaches to isolate bacteria from 
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urine samples, such as filtration or centrifugation, could be applied. Alternatively, an infected 
patient sample could be mixed with a selective broth to rule out growth of non-pathogenic 
microorganisms and then inoculated directly on the nwAST. Validation with 70 UPEC 
clinical strains demonstrated the clinical potential of the nwAST for UTI. Further validation 
with other species, however, is still needed to verify its broad applicability in the clinics.  
4.2 PAPER IV: A QUANTITATIVE REAL-TIME VIEW OF BACTERIAL 
PATHOGENESIS ON A SINGLE-CELL LEVEL 
We demonstrated how the field of organ-on-a-chip could revolutionize the study of bacterial 
pathogenesis. Infection in the PToC was in line with the principal findings of the rat intravital 
model, showing that we successfully mimicked in vitro the shear stress microenvironment of 
the proximal tubule. Owing to the temporal and single-cell resolution of the PToC, we were 
able to obtain a more refined view of bacterial colonization compared to in vivo experiments. 
Quantification of bacterial adhesion showed that only a small fraction of bacteria adhered. 
This adhesion was mainly transient, except for a few bacteria with long binding duration, 
which we termed as infection founders. PapG adhesin prolonged overall binding duration, but 
it was not a definitive requirement for long-term adhesion, as infection founders remained 
unaffected by its absence. In line with the phase variation observed for several E. coli 
adhesins (192), this suggested that the fimbrial profile greatly varies within a bacterial 
population, with only a small portion being suitably equipped to establish adhesion to renal 
cells under shear stress.  
Rapid proliferation of the few infection founders led to the spread of the infection but also to 
the formation of microcolonies. This lifestyle adaptation enabled bacteria to effectively 
overcome shear stress and colonize renal cells. In the in vivo context, this strategy would be 
advantageous for promoting colonization throughout the proximal tubule. During 
colonization, an unexpected role for FimH was shown. Besides its established role in direct 
adhesion to Uroplakin Ia of the urothelial plaques in the bladder, it mediated microcolony 
formation under shear stress, suggesting an involvement in interbacterial interactions. 
Although the absence of PapG or FimH adhesins slowed down the infection progression, 
bacteria eventually colonized host cells, causing them to round up and slough off. Taken 
together, these results suggested the involvement of several adhesion factors with redundant 
roles to secure the establishment of infection under shear stress. To further understand the 
complexity of adhesion to renal cells, the role of other fimbriae, such as F1C and Ygi, should 
be investigated (126)(193).  
Renal cells gradually rounded up and sloughed off, as bacterial colonization progressed. 
Disruption of the uroepithelium has been previously linked to the effect of the bacterial 
exotoxin α-hemolysin (41)(194). As the PToC is an excellent platform for real-time studies, 
future investigations could focus on the effect of α-hemolysin on epithelial disruption and the 
host’s immune response. Ischaemia is yet another hallmark of pyelonephritis, which is 
manifested in the renal vasculature surrounding the infected proximal tubule (195, 196). 
Ischaemia develops early during infection when bacteria are still contained within the 
 34 
proximal tubule with no direct contact with the endothelium, suggesting a molecular crosstalk 
between epithelium and endothelium. Addition of a second channel to PToC would enable us 
to create an endothelial-epithelial interface to study the molecular crosstalk that triggers blood 
clotting in the vasculature surrounding the infection site. As the field is moving towards a 
body-on-a-chip (197), connection of other organ-on-chips, such as the spleen (198), will 
elucidate the inter-organ communication during pyelonephritis and provide the complete 
picture of the pathophysiology of pyelonephritis.  
The development of novel in vitro models aims not only to increase understanding of 
bacterial pathogenesis but also to improve animal welfare in research. The main objectives of 
the "Three Rs" principles are to develop methods that replace, reduce and refine the use of 
experimental animal models (199). Here we demonstrated that organ-on-a-chip has the 
potential to reduce and replace animal use in research. Simulating the in vivo environment on 
a chip creates a credible platform to thoroughly test scientific hypotheses before performing 
animal experiments. With the addition of several tissue components and sensors, organ-on-a-
chip models have the potential to minimize or even replace the use of experimental animals. 
4.3 PAPER V: ESTABLISHING A LINK BETWEEN URINARY TRACT 
INFECTIONS AND BIOFILM 
We developed the first diagnostic assay for biofilm-associated infections based on cellulose 
optotracing. We demonstrated that UPEC adapts to a biofilm lifestyle as the bacteria colonize 
the urinary tract. As biofilm-associated infections can be hard to eradicate, it remains to be 
investigated whether failure of antibiotic treatment and recurrence of UTI are linked to 
biofilm. In contrast to laborious microscopy-based methods, in which interpretation of results 
is often subjective, optotracing delivers definitive cellulose detection in less than an hour, and 
it can be easily integrated into a clinical setting. Optotracing could also be applied for 
bacteriuria screening, based on its potential to differentiate between healthy and non-healthy 
urine. Ultimately, our diagnostic assay could help clinicians obtain a better clinical picture of 
the patient in order to choose an appropriate antibiotic therapy. 
As this is a proof-of-concept study, there are several additional steps to take before 
implementing this assay in the clinics. Improvement of urine processing to selectively isolate 
ECM from other host and bacterial components may increase the detection sensitivity of the 
assay. Moreover, the ECM of UPEC’s biofilm may also be without cellulose, which would 
go undetected by the current assay. Therefore, further screening of other LCOs could identify 
molecules to target additional ECM components and develop a multiplex biofilm-screening 
assay. Currently, there are no clinically established methods to detect cellulose, and therefore 
it was not possible to use a “gold standard” to describe the diagnostic accuracy of cellulose 
optotracing in urine. Other analytical methods may have to be explored. Contrary to the non-
disruptive nature of optotracing, however, these methods detect glucose, the building blocks 
of cellulose (200)(201). Taking into account the complexity and variability of a UTI urine 
sample, it would be difficult to establish such a reference method as glucose could also derive 
from other bacterial and host components.  
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5 MY CONTRIBUTION TO THE FIELD 
Although the field of microfabrication has generated a plethora of new devices with 
improved functions and design, they are largely underused in microbiology. In my thesis I 
bridged, microbiology with microfabricated devices to address pressing issues in infection 
biology. By integrating the nwSlide into my research, I tremendously increased throughput 
for both AST and phenotypic screening. In parallel, a line of new tools for research and 
diagnostics was developed, from algorithmic and heatmap analysis to a dual selection 
transposon and a one-step mutant phenotypic screening. My work also examined bacterial 
pathogenesis on a single-cell level with full-temporal resolution, showing the potential of the 
organ-on-a-chip concept for infection studies. By working at the intersection of LCO and 
microbiology, I also developed the first diagnostic tool for biofilm-associated UTI. Biofilm 
detection combined with AST could provide invaluable information to clinicians and help 
shape future strategies for biofilm-associated infection treatment. I hope that the papers 
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